Ovarian Embryonal Carcinoma
NCI Definition: An embryonal carcinoma arising from the ovary. Signs and symptoms include the presence of an abdominal mass and abdominal pain. 
Ovarian embryonal carcinomas most frequently harbor alterations in CDKN1B, ETV6, CCND2, RAD52, and KRAS .
CDKN1B Amplification, CCND2 Amplification, ETV6 Amplification, RAD52 Amplification, and KRAS Amplification are the most common alterations in ovarian embryonal carcinoma .
There are 6 clinical trials for ovarian embryonal carcinoma, of which 6 are open and 0 are completed or closed. Of the trials that contain ovarian embryonal carcinoma as an inclusion criterion, 2 are phase 1 (2 open) and 4 are phase 2 (4 open).
Ipilimumab, nivolumab, and aldesleukin are the most common interventions in ovarian embryonal carcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.